Keywords: genentech, drops, actimmune, renal, cell, carcinoma, decided

Genentech Drops Actimmune For Renal Cell Carcinoma

Article | 17 June 1996

Print This

Genentech has decided to discontinue the development of its Actimmune (interferon gamma-1b) product as a treatment for renal cell ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in